ADMA Biologics, Inc. ADMA
Analyst Ratings
- Consensus
- Moderate Buy — 2 Buy · 1 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $16.00 (+25.7% upside)
Key Stats
- Today's Range
- $12.52 – $13.20
- 50-Day Range
- $8.54 – $13.77
- 52-Week Range
- $7.21 – $20.46
- Volume
- 4.65 million shs
- Average Volume
- 3.74 million shs
- Market Cap
- $2.93 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.09%
- Days to Cover
- 1.12
About ADMA Biologics, Inc.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Related Stocks
Compare head-to-head: ADMA vs AMGN·ADMA vs MRNA·ADMA vs HALO·ADMA vs KYMR
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.